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ABSTRACT  
The mechanisms by which metformin 
(dimethylbiguanide) inhibits hepatic 
gluconeogenesis at concentrations relevant for 
type 2 diabetes therapy remain debated.  Two 
proposed mechanisms are: inhibition of 
mitochondrial Complex 1 with consequent 
compromised ATP and AMP homeostasis; or 
inhibition of mitochondrial glycerophosphate 
dehydrogenase (mGPDH) and thereby 
attenuated transfer of reducing equivalents from 
the cytoplasm to mitochondria resulting in a 
raised lactate/pyruvate ratio and redox-
dependent inhibition of gluconeogenesis from 
reduced but not oxidised substrates. Here we 
show that metformin has a biphasic effect on the 
mitochondrial NADH/NAD redox state in 
mouse hepatocytes. A low cell dose of 
metformin (therapeutic equivalent: < 2nmol / 
mg) caused a more oxidized mitochondrial 
NADH/NAD state and an increase in lactate / 
pyruvate ratio, whereas a higher metformin dose 
(≥5nmol/mg) caused a more reduced 
mitochondrial NADH/NAD state similar to 
Complex 1 inhibition by rotenone. The low 
metformin dose inhibited gluconeogenesis from 
both oxidized (dihydroxyacetone) and reduced 
(xylitol) substrates by preferential partitioning 
of substrate towards glycolysis by a redox-
independent mechanism that is best explained 
by allosteric regulation at phosphor-
fructokinase-1 (PFK1) and/or fructose 
bisphosphatase-1 (FBP-1) in association with a 
decrease in cell glycerol 3-P, an inhibitor of 
PFK1 rather than by inhibition of transfer of 
reducing equivalents. We conclude that at a low 
pharmacological load, the metformin effects on 
the lactate / pyruvate ratio and glucose 
production are explained by attenuation of 
transmitochondrial electrogenic transport 
mechanisms with consequent compromised 
malate-aspartate shuttle and changes in 
allosteric effectors of PFK1 and FBP1. 
   
--------------------------------------------------------- 
Metformin (dimethylbiguanide) is the 
most widely prescribed drug for lowering blood 
glucose in type 2 diabetes (1).  Its therapeutic 
effect is in part mediated by inhibition of hepatic 
glucose production (2), and is thought to involve 
chronic changes in gene expression (3-5) and 
acute inhibition of gluconeogenesis (6-8). The 
first mechanism that was identified for the acute 
suppression of gluconeogenesis was the 
inhibition of Complex 1 of the respiratory chain 
(NADH:ubiquinone oxidoreductase) with a 
consequent decrease in the cell ATP/ADP ratio 
in conjunction with a more reduced 
mitochondrial and cytoplasmic NADH/NAD 
redox state as determined from the raised ratios 
of 3-hydroxybutyrate / acetoacetate and lactate / 
pyruvate, respectively (9-13).  The inhibition of 
gluconeogenesis was attributed to either the 
decrease in the cell ATP/ADP ratio (9,10,14) or 
to activation of AMPK resulting from the raised 
AMP (15).   Subsequently, arguments were 
proposed in support of AMPK-independent 
mechanisms through either lowering of ATP or 
raised AMP (16) causing inhibition of glucagon 
signalling (17) or FBP1 (18) or alternatively 
through inhibition of mitochondrial 
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glycerophosphate dehydrogenase (mGPDH) 
(19,20).  Cellular studies using high millimolar 
metformin concentrations and showing 
substantial lowering of gluconeogenesis and cell 
ATP are now thought to be of limited relevance 
because in diabetes therapy blood metformin 
concentrations are in the low micromolar range 
and substantial lowering of ATP is thought not 
to occur during metformin therapy (1,6). 
Recently two distinct mechanisms have 
been proposed to explain the inhibition of 
gluconeogenesis by a pharmacological 
metformin dose of therapeutic relevance.    One 
proposes mild elevation in AMP through 
compromised hepatic energy status, resulting in 
inhibition of glucagon signalling (17) and 
allosteric inhibition of FBP1 (18).  The other 
proposes inhibition by metformin of mGPDH 
the key enzyme of the GP-shuttle, which is one 
of two shuttles that transfers reducing 
equivalents from the cytoplasm to the 
mitochondria (19,20).  mGPDH is a flavin-
linked mitochondrial dehydrogenase which 
catalyses G3P oxidation to dihydroxyacetone-P 
on the cytoplasmic side coupled to the reduction 
of FAD and transfer of electrons to the 
respiratory chain via ubiquinone (21). Inhibition 
of mGPDH by metformin is proposed to cause 
simultaneously a more reduced cytoplasmic 
NADH/NAD state evident from a higher lactate 
/ pyruvate ratio and a more oxidised 
mitochondrial NADH/NAD redox state evident 
from a lower ratio of 3-hydroxybutyrate / 
acetoacetate  (19,20).  A key caveat to this 
mechanism is that it predicts inhibition of 
gluconeogenesis from reduced substrates 
(lactate and glycerol) but not from oxidised 
substrates (pyruvate and dihydroxyacetone) 
whereas the first mechanism proposing 
inhibition of FBP1 by AMP predicts redox-
independent inhibition of gluconeogenesis from 
oxidised and reduced substrates.   A further 
caveat to the second mechanism is that it 
predicts a more oxidized mitochondrial 
NADH/NAD ratio (lower 3-hydroxybutyrate / 
acetoacetate) as opposed to a more reduced state 
as occurs by inhibition of Complex 1 and as 
documented from hepatocyte studies with 
metformin (9-12).  To date a more oxidised 
mitochondrial NADH/NAD ratio in response to 
metformin has only been shown in liver in vivo 
(19,20) but not in isolated hepatocytes.  The 
aims of this study were: first, to test whether 
metformin has a dose-dependent effect on the 
mitochondrial NADH/NAD ratio in 
hepatocytes; second, to explore the 
mechanism(s) by which a low metformin dose, 
equivalent of the therapeutic range, affects 
gluconeogenesis and compare this with 
inhibition and/or stimulation of transfer of 
NADH reducing equivalents from the 
cytoplasm to the mitochondria by the GP-shuttle 
or the MA-shuttle.  We report that clinically 
relevant doses of metformin cause a more 
oxidised mitochondrial NADH/NAD redox 
state and a more reduced cytoplasmic redox 
state but inhibit gluconeogenesis from oxidised 
substrates.  This is best explained by a redox-
independent mechanism involving allosteric 
regulation at the level of PFK1 and/or FBP1 that 
is in part explained by a decrease in cell glycerol 
3-P an inhibitor of PFK1. 
 
RESULTS 
Biphasic effect of metformin on the 
mitochondrial redox state: more oxidized at 
low metformin 
Studies in vivo showed that metformin 
causes either a more reduced (10) or a more 
oxidized (19,20) mitochondrial NADH/NAD 
redox state in liver based on the ratio of 3-
hydroxybutyrate / acetoacetate which correlates 
with the mitochondrial NADH/NAD ratio 
through the hydroxybutyrate dehydrogenase 
equilibrium (22).  Our first aim was to determine 
whether metformin (100-500 µM) has a dose-
dependent effect on the mitochondrial 
NADH/NAD redox state in hepatocytes 
incubated with octanoate.  This medium-chain 
fatty acid enters the mitochondria as the free 
acid by a mechanism independent of regulation 
by malonyl-CoA and thereby AMPK activity 
and is metabolised predominantly to 
acetoacetate and 3-hydroxybutyrate.  We used 
100 µM as the lowest metformin concentration 
because in hepatocytes incubated with 100 µM 
metformin for 2-4h metformin accumulates in 
the cells to 1-2 nmol / mg protein (23).  This is 
within the range observed in mouse liver after 
an oral dose of 50mg metformin /kg body wt 
(24). At the highest concentration (500 µM) 
metformin  accumulates to 5-10 nmol/mg (23) 
in rat and mouse hepatocytes.  In both mouse 
and rat hepatocytes, high metformin (500 µM) 
increased the ratio of 3-hydroxybutyrate / 
acetoacetate as did rotenone, the Complex I 
inhibitor (Fig. 1A,D), and as shown previously 
with mM metformin in hepatocytes (9-12).  
However, 100 µM metformin decreased the 3-
hydroxybutyrate / acetoacetate ratio (Fig. 
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1,A,D) indicating a more oxidised 
mitochondrial NADH/NAD state (22).  This 
effect could be due to a decrease in production 
of NADH (if octanoate β-oxidation were 
inhibited) or to other mechanisms.  The rate of 
production of acetoacetate plus 3-
hydroxybutyrate was increased by 100 µM 
metformin in both mouse and rat hepatocytes 
and it was also increased by the uncoupler 
dinitrophenol, DNP (Fig. 1B,E), which similar 
to low metformin decreased the 3-
hydroxybutyrate / acetoacetate ratio (Fig. 1D).  
This implicates a more oxidised NADH/NAD 
state as the primary effect of 100 µM metformin 
with the increase in ketone body production as 
secondary to the oxidized NADH/NAD ratio.  
When the effects of low metformin and DNP 
were tested in the presence of rotenone (Fig. 
1G,H), only DNP lowered the 3-
hydroxybutyrate / acetoacetate ratio, suggesting 
that the metformin effect is either upstream of 
the rotenone site or alternatively abolished by 
rotenone through other mechanisms.  Although 
cell ATP was maintained in cells treated with 
metformin (Fig. 1C,F), this does not exclude 
small localized changes in free ATP/ADP ratio 
in the cytoplasm (10).  We next tested for 
activation of AMPK by the low and high 
metformin concentrations from phosphorylation 
of the AMPK substrate, acetyl-CoA 
carboxylase-Ser-79 (ACC-S79) and used the 
small molecule AMPK activator A-769662 (10 
µM) as a reference control (25) in incubations 
without and with octanoate in mouse 
hepatocytes (Fig. 1K).  The high metformin 
concentration (500 µM) caused increased ACC 
phosphorylation as occurred with A-769662.  
Octanoate alone also increased ACC 
phosphorylation indicating AMPK activation.  
This suggests raised AMP with octanoate most 
likely via the acyl-CoA synthase as reported 
previously (26).  There was lower 
phosphorylation of ACC by 100 µM metformin 
in combination with octanoate. This may be due 
to accelerated clearance of octanoate by 100 µM 
metformin. 
 
Metformin causes greater inhibition of glucose 
production from dihydroxyacetone than from 
glycerol  
      Having confirmed that low metformin (100 
µM) causes a more oxidised mitochondrial 
NADH/NAD redox state without inhibiting 
ketone body production we next determined the 
effects of 100 µM metformin on glucose 
production from oxidized (dihydroxyacetone, 
DHA) and reduced (glycerol and xylitol) 
substrates.  Glucose production was 
significantly higher from DHA than from 
glycerol (Fig. 2).  Metformin inhibited glucose 
production from both oxidised (DHA) and 
reduced (xylitol and 0.25mM glycerol) 
substrates and it increased the production of 
lactate and pyruvate with both DHA and xylitol 
(Fig. 2A,B).  Cell ATP was unchanged by 
metformin with DHA but was lowered with the 
reduced substrates (Fig. 2C).  This indicates 
inhibition of gluconeogenesis from both 
oxidised and reduced substrates by low 
metformin. 
 
Low metformin but not inhibitors of the NADH 
shuttles favours metabolism of DHA and 
xylitol to glycolysis relative to glucose 
      To test whether inhibition of glucose 
production by low metformin can be explained 
by inhibition of NADH shuttles we compared 
100 µM metformin with aminooxyacetate 
(AOA), an inhibitor of the malate-aspartate 
shuttle (MA-shuttle) (27), or GPi (STK017597, 
GPI), a recently identified inhibitor (28) of the 
GP-shuttle, on metabolism of DHA (Fig. 3A-F) 
or xylitol (Fig. 3G-L) in either the absence (open 
bars) or presence (shaded bars) of octanoate as 
a source of mitochondrial NADH.  Metformin 
inhibited glucose production and increased 
lactate plus pyruvate production without 
affecting total metabolism to glucose plus 
pyruvate and lactate from DHA (Fig. 3A-C) or 
xylitol (Fig.3 G-I).  Accordingly, metformin 
decreased the fractional partitioning of DHA 
and xylitol to glucose relative to glycolysis (Fig 
3D, Fig 3J).  Octanoate (shaded bars) had 
opposite effects from metformin and increased 
partitioning of DHA and xylitol to glucose 
relative to glycolysis with no significant effect 
on total metabolism (Fig. 3A-D; 3G-J). Both the 
lactate/pyruvate ratio and cell G3P were higher 
with the reduced substrate xylitol (Fig. 3KL) 
than with DHA (Fig. 3EF), as expected (29), and 
octanoate increased the lactate/pyruvate ratio 
with DHA (Fig. 3E) but not with xylitol (Fig. 
3K).  Metformin increased the lactate/pyruvate 
ratio with both DHA and xylitol but decreased 
G3P (Fig. 3EK; Fig. 3FL).  The MA-shuttle 
inhibitor, AOA caused a large increase in the 
lactate/pyruvate ratio, as expected (27), but the 
GPi had a smaller effect than AOA.  Unlike 
metformin, AOA increased G3P (Fig. 3FL) and 
did not decrease partitioning of DHA to glucose.  
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AOA decreased total metabolism of the reduced 
substrate xylitol to glucose, pyruvate and lactate 
(Fig. 3I).  Cumulatively, these results support 
the following conclusions.  First, that low 
metformin inhibited glucose production from 
both oxidized (DHA) and reduced (xylitol) 
substrates by increasing partitioning to 
glycolysis, with a concomitant increase in 
lactate / pyruvate ratio and a decrease in cell 
G3P.  Second, that AOA which caused a more 
reduced cytoplasmic redox state (lactate / 
pyruvate ratio) than metformin did not mimic 
the metformin inhibition of gluconeogenesis 
from DHA but it decreased total xylitol 
metabolism and increased cell G3P.  Third, that 
the inhibitor of mGPDH (GPi 20µM) was less 
effective than the MA-shuttle inhibitor (AOA) 
in raising the lactate / pyruvate ratio and did not 
raise cell G3P, the substrate of mGPDH.  
Fourth, that octanoate which promotes an 
increase in lactate/pyruvate ratio with DHA but 
not with xylitol had opposite effects from 
metformin on the directionality of flux between 
glycolysis and gluconeogenesis with both DHA 
and xylitol as substrates. 
 
GPi (STK017597) but not metformin inhibits 
endogenous mGPDH activity in hepatocytes 
       The greater effect of the MA-shuttle 
inhibitor (AOA) compared with the mGPDH 
inhibitor (GPi, STK017597) on the 
lactate/pyruvate ratio could be due to either a 
greater contribution of the MA-shuttle 
compared with the GP-shuttle to transfer of 
reducing equivalents from the cytoplasm to 
mitochondria, or to poor efficacy or cellular 
uptake of GPi by hepatocytes.  We next tested 
the effects of the GPi and metformin on 
mGPDH activity in permeabilised hepatocytes 
using the electron acceptor dichlorophenol 
indophenol (31) and confirmed inhibition of 
mGPDH activity by 10-80 µM GPi (Fig. 4A) as 
reported previously (28), but not with 
metformin at 0.1 to 5 mM (Fig. 4B).  Although 
STK017597 is a potent mGPDH inhibitor in 
permeabilised hepatocytes, it may be ineffective 
in the intact hepatocytes because of slow 
transport or low functional GP-shuttle activity.  
In additional experiments with 80 µM GPi in 
hepatocytes that were either untreated or treated 
with an adenoviral vector to overexpress 
mGPDH (Fig.5) there was an increase in G3P 
with 80 µM GPi in the untreated hepatocytes 
consistent with endogenous functional mGPDH 
activity (Fig. 5A). However partitioning of 
DHA to glucose was not inhibited by 80 µM GP 
(Fig. 5B-E). 
 
Overexpression of mGPDH lowers cell G3P 
and promotes a more reduced mitochondrial 
NADH/NAD ratio and increased glycolysis 
To further test the role of the GP-shuttle in 
glycolysis and gluconeogenesis we used 
adenoviral vectors for overexpression of 
mGPDH or shRNA knock-down in mouse 
hepatocytes and confirmed an increase or 
decrease, respectively in Gpd2 mRNA after 24h 
(Fig. 4C).  We also confirmed overexpression of 
mGPDH protein by immunoblotting and the 
activity assay with 2 adenoviral titres (Fig. 
4D,E) but there was little suppression of 
mGPDH activity by sh-RNA knock-down, 
presumably because of the long half-life of 
mGPDH protein (21).  We therefore used two 
levels of mGPDH overexpression (as in Fig. 
4D,E) for metabolic studies (Fig. 6-8).  With 
25mM glucose and octanoate as substrates 
mGPDH overexpression was associated with 
lower levels of cell G3P (Fig. 6A) and with a 
more reduced mitochondrial NADH/NAD 
redox state (Fig. 6B), but decreased production 
of ketone bodies (Fig. 6C) and thereby β-
oxidation of octanoate.  The production of 
lactate and pyruvate was slightly raised (Fig. 
6D) with negligible change in the lactate / 
pyruvate ratio (Fig. 6E).  The more reduced 
mitochondrial NADH/NAD redox state in 
conjunction with lower cell G3P confirms that 
overexpressed mGPDH is appropriately 
targeted to the mitochondrial membrane and is 
functional such that G3P oxidation is associated 
with transfer of reducing equivalents to 
mitochondria and presumably reversed electron 
transport resulting in both a raised NADH/NAD 
and suppression of β-oxidation.  Inhibition of 
the MA-shuttle with AOA, unlike 
overexpression of mGPDH, had negligible 
effect on the mitochondrial redox state but it 
counteracted and reversed the effect of low 
metformin on the mitochondrial redox state 
(Fig. 1-I,J). 
 
Overexpression of mGPDH promotes DHA 
metabolism to glycolysis rather than glucose 
and does not increase xylitol metabolism 
      A role for mGPDH in the control of 
gluconeogenesis has previously been inferred 
from lower blood glucose in some mouse 
models of Gpd2 deficiency (19,20,32-34) and 
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from association studies in hepatocytes from 
rodents with altered thyroid hormone signalling 
and raised mGPDH activity (35).  In the latter 
study (35) mGPDH was one of a number of 
genes showing altered expression with thyroid 
status. To test the specific role of mGPDH in 
control of gluconeogenesis, we determined the 
effects of mGPDH overexpression on rates of 
glucose production from oxidised and reduced 
substrates.  With DHA as substrate (Fig. 7A-F), 
overexpression of mGPDH was associated with 
lower cell G3P, and increased production of 
pyruvate plus lactate but not glucose or total 
DHA metabolism and accordingly with 
decreased partitioning of DHA to glucose (Fig. 
7A-E).  This was associated with a raised lactate 
/ pyruvate ratio (Fig. 7F).  Likewise with DHA 
plus octanoate in incubations without or with 
AOA, to inhibit the MA-shuttle (Fig. 7G-L), 
there was also lowering of G3P and increased 
production of pyruvate plus lactate and 
decreased partitioning of DHA to glucose with 
mGPDH overexpression.  With xylitol as 
substrate and without or with AOA to inhibit the 
MA-shuttle (Fig. 8A-C), both cell G3P and the 
lactate to pyruvate ratio were markedly elevated 
by MA-shuttle inhibitor and total xylitol 
metabolism was inhibited indicating an essential 
role for the MA-shuttle in regenerating NAD 
consumed by xylitol oxidation to xylulose.  
Overexpression of mGPDH markedly lowered 
cell G3P but did not reverse the AOA effect on 
total xylitol metabolism and had negligible 
effect on the lactate /pyruvate ratio (Fig. 8A-C). 
 
Overexpression of mGPDH increases total 
metabolism of glycerol 
     We next determined the effects of mGPDH 
overexpression on glycerol metabolism (Fig. 
8D-I).  Cell G3P was markedly lowered and 
total glycerol metabolism to glucose, pyruvate 
and lactate was increased mainly as a result of 
an increase in pyruvate and lactate production 
(Fig. 8D-G). Increased mGPDH activity 
favoured increased glycerol metabolism by 
preferential partitioning to glycolysis relative to 
glucose (Fig. 8H).  Cumulatively, 
overexpression of mGPDH caused: a marked 
decrease in cell G3P with all substrates tested 
(glucose, DHA, xylitol, glycerol), (Figs 6-8), 
and a more reduced mitochondrial NADH/NAD 
state (Fig. 6).  With DHA as substrate the effects 
of mGPDH overexpression (Fig. 7) mimicked 
the effect of metformin (Fig. 3) in favouring 
partitioning to glycolysis relative to glucose.   
 
Metformin inhibition of gluconeogenesis from 
DHA is abolished by allosteric targeting at 
PFK1 and FBP1 
     The above studies suggest that the metformin 
inhibition of glucose production from DHA and 
xylitol (Fig 3), which occurs in conjunction with 
lowering of cell G3P is not mimicked by 
inhibition of either the MA-shuttle (Fig. 3) or 
the GP-shuttle (Fig. 5).  We next considered 
allosteric regulation at PFK1 and/or FBP1 as a 
candidate mechanism for the effect of low 
metformin on glycolysis and gluconeogenesis 
because previous work showed that the 
inhibition of glycolysis by octanoate is in part 
explained by raised citrate, a potent inhibitor of 
PFK1 (36,37).  To test for regulation at PFK1 or 
FBP1 we expressed a kinase-deficient variant 
(PFK-KD) of the bifunctional enzyme 
PFK2/FBP2, which depletes cell fructose 2,6-P2 
(38), a potent activator of PFK1 and inhibitor of 
FBP1 (39) and we compared metformin (100 
µM) with the activator of AMPK  (A-769662, 
10 µM) in cells that were either untreated or 
depleted of fructose 2,6-P2 (Fig. 9, open vs 
shaded bars).  Depletion of fructose 2,6-P2 (with 
Adv-PFK-KD) increased glucose production 
and decreased glycolysis consistent with 
decreased PFK1 and increased FBP1 activity 
(39).  In untreated cells metformin (100µM) and 
A-769662 had opposite effects (inhibition and 
stimulation, respectively) on relative 
partitioning of DHA to glucose (Fig 9 A-D).  
These effects of metformin and A-769662 were 
attenuated by fructose 2,6-P2 depletion (Fig 9, 
shaded bars). Cumulatively, this shows that the 
metformin effect is not mimicked by activation 
of AMPK and is attenuated by depletion of 
fructose 2,6-P2 an allosteric regulator of both 
PFK1 and FBP1.  We next used an inhibitor of 
FBP1 that binds to the AMP-site (40) and a 
citrate analogue inhibitor of PFK1 (ATA, 
aurintricarboxylic acid) which antagonizes 
activation of PFK1 by AMP and fructose 2,6-P2 
(41), to selectively target FBP1 or PFK1 (Fig. 
10).  For these studies we used the chlorogenic 
acid derivative, S4048 (200nM) which is a 
selective inhibitor of the G6P transporter 
Slc37a4 (42), to raise cell G6P which is 
otherwise below detection limits in hepatocytes 
incubated in glucose-free medium.  The FBP1 
inhibitor, lowered glucose production from 
DHA and cell G6P whereas the PFK1 inhibitor 
raised glucose production and G6P (Fig. 
10A,B).  The PFK1 inhibitor caused partitioning 
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of substrate towards glucose despite attenuation 
of total DHA metabolism (Fig. 10C-E).  The 
inhibition of gluconeogenesis and the lowering 
of cell G6P by metformin were abolished by the 
PFK1 and FBP1 inhibitors (Fig. 10A,B). 
Cumulatively, this points to a significant 
contribution of allosteric control of PFK1 and 
FBP1 in the partitioning of DHA metabolism 
between glycolysis and gluconeogenesis and in 
the metformin inhibition of glucose production.  
 
 
DISCUSSION  
Although metformin has been used for 
Type 2 diabetes therapy for several decades 
(1,2), the mechanisms by which it inhibits 
hepatic gluconeogenesis remain debated (4-20).  
Two contentious issues are: what metformin 
exposure in cellular models is the equivalent of 
therapeutic exposure in human diabetes (1,5,18) 
and whether the acute inhibition of 
gluconeogenesis is explained by compromised 
energy status via inhibition of Complex 1 (9-18) 
or by a redox-dependent mechanism through 
inhibition of mGPDH and thereby the GP-
shuttle (19,20).  
The MA-shuttle and the GP-shuttle 
together with production of lactate by lactate 
dehydrogenase are the three major mechanisms 
in liver that lead to the regeneration of NAD that 
is consumed in glycolysis (Fig. 11).  Flux 
through the GP-shuttle is determined by the 
activity of mGPDH, which is expressed at 
relatively low levels in liver compared with 
brain, muscle and thermogenic brown adipose 
tissue (21).  Nonetheless it is adaptively 
regulated in liver by thyroid and steroid 
hormone status and it is also allosterically 
regulated by Ca2+ (21).  Altered activity of 
mGPDH could therefore result in variable 
contribution of this shuttle to the cytoplasmic 
and mitochondrial redox state.  Mice with 
selective disruption of either the GP-shuttle by 
knock-down of mGPDH or the MA-shuttle by 
knock-down of citrin, the electrogenic aspartate 
transporter, have a modest phenotype with 
respect to fasting blood glucose (32-34), though 
with a greater role of the MA-shuttle compared 
with GP-shuttle in lowering blood glucose (34).  
However combined knock-down of both 
mGPDH and citrin resulted in significant 
disruption of blood glucose and glycerol levels, 
indicating that both shuttles can mutually 
compensate when either shuttle is genetically 
deleted (34).  In the present study we used 
inhibitors of the MA-shuttle and GP-shuttle and 
we overexpressed mGPDH to explore the role 
of these shuttles in the maintenance of 
cytoplasmic and mitochondrial NADH/NAD 
redox state and metabolism of oxidized and 
reduced substrates.  We show that inhibition of 
the MA-shuttle causes a more reduced 
cytoplasmic redox state but with negligible 
effect on the mitochondrial redox state whereas 
overexpression of mGPDH causes a more 
reduced mitochondrial redox state, but with 
variable effects on the lactate / pyruvate ratio 
depending on the substrate conditions.  We used 
a metformin concentration and exposure time in 
hepatocytes, that results in cellular metformin 
levels (1-2 nmol/mg) (23) that are attained in 
mouse liver after an oral metformin dose 
equivalent to the therapeutic dose (50mg/kg or 
3g per 60kg) (24).  Two key findings from the 
present study are, first that low metformin 
promotes a decrease in 3-hydroxybutyrate/ 
acetoacetate ratio (more oxidized mitochondrial 
NADH/NAD) but an increase in lactate/ 
pyruvate ratio (more reduced cytoplasmic 
NADH/NAD) as with a low dose of metformin 
in vivo in liver (19,20) and kidney (43,44); 
second, that low metformin inhibits 
gluconeogenesis from oxidized and reduced 
substrates by preferential partitioning to 
glycolysis and with concomitant lowering of 
cell G3P.  This inhibition of gluconeogenesis 
cannot be explained by inhibition of either the 
MA-shuttle or the GP-shuttle and is best 
explained by allosteric regulation at the level of 
PFK1 and FBP1.  These two effects of 
metformin are discussed separately. 
The increase in lactate/pyruvate ratio is 
probably the most widely documented effect of 
metformin in vivo (19,20,43) and in vitro (9-
12,14).  Although an increase in lactate/ 
pyruvate ratio by a high metformin dose is 
frequently attributed to inhibition of Complex I 
and thereby the respiratory chain, the increase 
by low metformin in conjunction with a more 
oxidized mitochondrial NADH/NAD state 
requires other explanations.  One possible 
explanation for this is inhibition of mGPDH 
(19,20).  However, in this study cell G3P, the 
substrate of mGPDH was lowered by metformin 
and by mGPDH overexpression and was 
increased with the mGPDH inhibitor.  This does 
not support a role for inhibition of GP-shuttle 
activity by metformin and accordingly other 
explanations need to be considered for the 
increase in lactate/pyruvate ratio by low 
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metformin.  Flux through the MA-shuttle 
involves an electrogenic transporter for 
aspartate and is highly dependent on 
mitochondrial membrane potential (45-48).  The 
most plausible explanation for the increase in 
lactate / pyruvate ratio by low metformin is that 
it results from accumulation of metformin in 
mitochondria with consequent mitochondrial 
depolarisation (9,49) and inhibition of the MA-
shuttle (45-48) through attenuation of 
electrogenic transport (Fig. 11).  The biphasic 
effect of metformin on the ratio of 3-
hydroxybutyrate / acetoacetate in hepatocytes 
suggests that metformin inhibits Complex I at 
the higher concentration which corresponds to a 
cell load ≥ 5 nmol metformin / mg cell protein 
but not at 100 µM which corresponds to  ≤2nmol 
metformin / mg protein.  A key question is what 
is the mechanism for the oxidized mitochondrial 
NADH/NAD state by low metformin?   Detailed 
studies by Bridges and colleagues (13) on the 
effects of metformin on the sequential reactions 
of complex 1 (NADH oxidation, electron 
transfer and ubiquinone reduction) showed that 
metformin interacts with at least two sites, the 
flavin site and the ubiquinone site.  Metformin 
activates the first reaction, NADH oxidation 
when this is coupled to the artificial electron 
acceptor FeCN but it inhibits reversibly at the 
ubiquinone site by a distinct mechanism from 
canonical Complex I inhibitors (e.g. rotenone) 
which bind irreversibly.  Whether low 
metformin concentrations (below the threshold 
for inhibition of the ubiquinone site) could 
lower the NADH/NAD ratio through 
metformin’s effect at the flavin site is 
speculative because the rate constant for NADH 
oxidation is far higher than for ubiquinone 
reduction (50). A simpler explanation is that 
depolarisation of the mitochondria by 
metformin accumulation in mitochondria 
accounts for the lower NADH/NAD ratio by 
increased flux through Complex I as occurs 
during depolarisation with the uncoupler 
dinitrophenol because flux through Complex 1 
is impeded by the proton motive force.  
Accordingly mitochondrial depolarisation by 
metformin accumulation could in principle 
account for both the oxidized mitochondrial 
redox state and the reduced cytoplasmic redox 
state. 
We show in this study that the inhibition 
of gluconeogenesis by the low dose of 
metformin cannot be explained by either 
inhibition of Complex 1, (because of the more 
oxidized mitochondrial redox state) or 
activation of AMPK, (because AMPK 
activation has the converse effect on DHA 
metabolism from metformin) or by inhibition of 
transfer of reducing equivalents from the 
cytoplasm to the mitochondria because 
inhibition of these shuttles does not mimic 
metformin on DHA metabolism.  Based on the 
large effects of the inhibitors of PFK1 and FBP1 
or by depletion of fructose 2,6-P2 , the allosteric 
regulator of both PFK1 and FBP1 that acts 
synergistically with other effectors (39), on the 
directionality of flux between glycolysis versus 
gluconeogenesis and also the attenuation of the 
metformin effect by these inhibitors, we propose 
that allosteric regulation at the level of PFK1 
and FBP1 is the most plausible explanation for 
the metformin effect on gluconeogenesis and 
glycolysis.  FBP1 is regulated synergistically by 
AMP and fructose 2,6-P2 and PFK1 is regulated 
by multiple positive effectors (e.g. AMP, 
fructose 2,6-P2,  fructose 1,6-P2,  glucose 1,6-P2   
and Pi) and negative effectors (ATP, citrate, 
G3P) (39).  If the increase in the lactate/pyruvate 
ratio by low metformin is consequent to 
mitochondrial depolarisation and inhibition of 
the electrogenic transporter of the MA-shuttle 
(45-48), then other electrogenic transport 
mechanisms would likewise be expected to be 
attenuated.  One such mechanism is the adenine 
nucleotide transporter (ANT) which exchanges 
ADP3- on the cytoplasmic side for ATP4- on the 
mitochondrial side (51,52).  An increase in the 
cytoplasmic ADP/ATP ratio would be expected 
to result from mitochondrial depolarisation.  
Other allosteric effectors of PFK1 which may 
contribute to stimulation of glycolysis include 
citrate which is a potent PFK1 inhibitor and has 
been shown to be lowered by metformin 
treatment in some models of diabetes (53) and 
G3P which is a potent inhibitor of PFK1 (54).  
In this study cell G3P was decreased by low 
metformin in conditions of raised glycolysis and 
decreased gluconeogenesis and likewise G3P 
was decreased in cells overexpressing mGPDH 
which showed similar partitioning of DHA 
towards glycolysis as with metformin.  The 
lowering of cell G3P by metformin in conditions 
of raised lactate / pyruvate ratio may result from 
increased flux through the GP-shuttle in 
conditions of impaired MA-shuttle flux because 
of mitochondrial depolarisation.  The more 
reduced mitochondrial redox state by metformin 
in the presence of the MA-shuttle inhibitor 
supports this explanation.  Cumulatively, this 
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supports the conclusion that low metformin 
concentrations which do not inhibit Complex I, 
can inhibit gluconeogenesis by a redox 
independent mechanism through allosteric 
regulation of PFK1 and FBP1 in conjunction 
with lowering of cell G3P and an increase in 
lactate /pyruvate ratio.  The latter effects may be 
due to altered flux through the MA-shuttle and 
GP-shuttle (inhibition and stimulation, 
respectively). 
 
 
Experimental procedures 
Reagents:  STK017597 (GPI), an inhibitor of 
mGPDH (28) was from Vitas-M Laboratory; A-
769662 was from Tocris Biosciences; the FBP1 
inhibitor, (5-chloro-2-[N-(2,5dichlorobenzene 
sulfonamide)]-benzoxazole (40) was from 
Calbiochem/Santa cruz.  S4048, the chlorogenic 
acid derivative (1-[2-(4-chloro-phenyl)-
cyclopropylmethoxy]-3, 4-dihydroxy-5-(3-
imidazo[4,5-b]pyridin-1-yl-3-phenyl-
acryloyloxy)-cyclohexanecarboxylic acid) (42) 
was a kind gift from Sanofi-Aventis.  All other 
reagents were from Sigma.  
 
Adenoviral vectors: for overexpression of 
mouse mGPDH (Ad-m-Gpd2, ADV-279685; 
RefSeq BC021359) and for sh-RNA knock-
down (ADV-m-Gpd2-shRNA, shADV-279685; 
RefSeq NM-010274) were generated by Vector 
Biolabs, Malvern, PA 19355.   The adenoviral 
vector for expression of a kinase-deficient 
variant of PFKFB1 (S32D, T55V) denoted by 
PFK-KD for a bisphosphatase-active kinase-
deficient variant of 6-phosphofructo-2-kinase–
fructose-2,6-bisphosphatase was described in 
(38).  
 
Hepatocyte isolation and culture:  
Hepatocytes were isolated by collagenase 
perfusion of the liver either from adult male 
Wistar rats (200-280 g body wt) or from adult 
male C57BL/6JOlaHsd mice (20-30 g body wt) 
obtained from Harlan/Envigo (Bicester UK).  
Unless otherwise indicated mouse hepatocytes 
were used.  Rat and mice were housed in 
environmental conditions as outlined in the 
Home Office Code or Practice.  Procedures 
conformed to Home Office Regulations and 
were approved by the Newcastle University 
Ethics Committee. Rat hepatocytes were 
isolated at previously described (38).  For 
mouse hepatocyte isolation, euthanasia was by 
isoflurane overdose followed by heparin 
injection and laparotomy.  The liver was 
perfused at 5 ml/min for 5 min with Ca-free 
Hanks buffer followed by 20 min with Hanks 
buffer containing 0.1mg/ml collagenase (Sigma 
C5138). After sedimentation at 50g the 
hepatocytes were suspended in Minimum 
Essential Medium (MEM, Life Technologies 
21430) supplemented with 5% (v/v) newborn 
calf serum and 10nM dexamethasone and 10nM 
insulin and seeded on gelatin-coated (0.1% 
wt/vol) multi-well plates.  After cell attachment 
the medium was replaced by serum-free MEM 
containing 5mM glucose, 10nM 
dexamethasone, 1nM insulin and the 
hepatocytes were cultured overnight (~16-20 h). 
 
Treatment with adenoviral vectors:  For 
protein overexpression 2h after cell attachment 
the serum-containing medium was replaced by 
serum-free MEM containing Ad-m-Gpd2 
(ADV-279685; Ref Seq BC021359, Vector 
Biolabs Malvern, PA) at titres of 1.6 and 4.8 x 
107 PFU/ml for overexpression of mouse 
mGPDH or with PFK-KD for expression of a 
kinase-deficient variant of PFK2/FBP2 (Pfkfb1: 
S32D, T55V) for depletion of fructose 2,6-P2 
(38).  After 4h the medium was replaced by 
serum-free MEM containing 10nM 
dexamethasone and 1nM insulin and the 
hepatocytes were cultured for 18-20h. 
 
Hepatocyte incubations with metformin:  All 
experiments with metformin were performed 
after 16-20h culture with the exception of Fig 
1G to 1J, which was started 3h after cell plating.  
The hepatocyte monolayers were pre-incubated 
with metformin for 2h with either MEM 
containing 5 mM glucose or glucose-free 
DMEM (Life technologies, A14430). After 2h 
the medium was replaced by fresh MEM or 
glucose-free DMEM medium with the same 
metformin concentrations and other substrates 
(e.g. octanoate and gluconeogenic precursors) 
as indicated for either 1h (acetoacetate + 3-
hydroxybutyrate) or 2h (glucose production 
studies).   On termination of the incubations the 
medium was collected for determination of 
acetoacetate, 3-hydroxybutyrate, lactate, 
pyruvate and glucose and the hepatocyte 
monolayers were snap-frozen in liquid nitrogen 
and stored at -80oC until analysis.    
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Metabolite assays:   For determination of 
ketone bodies and pyruvate the medium was 
acidified with 0.2 volume of 0.6M HClO4.  
Acetoacetate and 3-hydroxybutyrate were 
assayed using 3-hydroxybutyrate 
dehydrogenase and pyruvate and lactate using 
lactate dehydrogenase from the change in 
NADH fluorescence (Ex 340, Em 460) as in 
(55).  Ketone body production is expressed as 
nmol / h per mg protein (mouse hepatocytes) or 
as % control (rat hepatocytes Fig. 1D-F).    
Glucose was determined by the hexokinase, 
glucose 6-phosphate dehydrogenase coupled 
assay (56).  Production of pyruvate plus lactate 
or glucose are expressed as nmol / 2h per mg 
protein and glucose production is also expressed 
as % of total production of pyruvate + lactate + 
glucose (expressed as C3 units).  For 
determination of cell ATP, G3P and G6P the 
hepatocyte monolayers were extracted 2.5% 
(wt/vol) 5-sulfosalicylic acid and deproteinized 
by sedimentation at 10,000g, 10min.  The 
supernatant was neutralised with 1M-KOH, 
0.66M-K2HPO4 and cell ATP was determined 
by a luciferase coupled luminometric method 
(Sigma FLAA), G6P and G3P were assayed 
using glucose 6-phosphate dehydrogenase and 
glycerol 3-phosphate dehydrogenase, 
respectively by coupling to resazurin conversion 
to resorufin with diaphorase (Ex 530, Em 590) 
(57).  Standards for the assays were prepared 
fresh in culture medium or 2.5% 5-sulfosalicylic 
acid and concentrations were determined from 
standard curves and expressed as nmol / mg 
protein determined by the Lowry assay. 
 
Activity of mGPDH was determined on 
hepatocyte monolayers that were snap-frozen in 
liquid nitrogen and stored at -80oC until 
analysis.  The assay medium containing 200mM 
sucrose, 50mM KPi pH 7.6, 200 µM DCIP and 
25mM DL-G3P and activity was determined 
from the decrease in absorbance at 600 nm using 
the extinction in (31).  
Western blotting:   Immunoactivity to mouse 
mGPDH (Proteintech, #17219-1Ap); GAPDH 
(Hytest ABIN153387); and ACC-ser-79(P) 
(Cell Signalling #11818) were determined by 
SDS-PAGE using 8% (ACC) or 12% (Gpd2) 
SDS and immunoblotting. They were quantified 
by densitometry.  
RNA analysis:  RNA was extracted with Trizol 
and cDNA synthesized by MMLV.   The 
primers used for real-time RT-PCR were: Gpd2, 
Forward, ACTACCTGAGTTCTGACGTTG 
AAG; reverse, TAACAAGGGGACGGATAC 
CA; Gapdh, forward,  GAC AAT GAA TAC 
GGCTACAGCA; reverse GGC CTC TCT 
TGCTCAGTGTC.  
Statistical analysis.  Results for all data sets 
other than Figure 2 are expressed as means ± SD 
for the number of hepatocyte preparations 
indicated and statistical analysis was either by 
the Student’s paired t-test or by one-way 
ANOVA.  For Figure 2 the data represents 
replicate incubations in a single hepatocyte 
preparation. 
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FIGURE 1. Biphasic effect of metformin on the mitochondrial redox state: more oxidized at low 
metformin.   Mouse hepatocytes (A-C) and rat hepatocytes (D-F) were pre-cultured for 24h and then incubated for 
2h in MEM with the metformin concentrations (100‐500μM) indicated. The medium was then replaced with fresh 
MEM containing 25mM glucose, 0.25mM octanoate and the additions shown and incubations were for 1h. The 
medium was collected for analysis of acetoacetate (Acac) and D-3-hydroxybutyrate (HOB) and the cells were snap-
frozen for ATP analysis. A,D ratio of 3-hydroxybutyrate / acetoacetate; B,E total production of acetoacetate + 3-
hydroxybutyrate; C,F Cell ATP.  Mouse data is expressed per mg protein and rat data as % control.  Means ± SD for n= 
8-14 hepatocyte preparations, *P < 0.05 relative to control.  
G-J. Mouse hepatocytes cultured for 3h after cell plating then incubated for 2h without (open) or with (shaded) 100 
μM metformin (G,I) and then for 1h in fresh MEM containing 25mM glucose + 0.125mM octanoate and the additions 
indicated:  G and H effects of metformin (100 µM) or DNP, dinitrophenol (20μM) -/+ rotenone (0.1 or 0.25μM); I and 
J -/+ aminooxyacetate (200μM AOA).  Means ± SD for n=5-7, * P < 0.05 relative to respective control; $, metformin or 
DNP effect.   K. Immunoblot for phospho-ACC for mouse hepatocytes incubated ‐/+ metformin (100 or 500μM) and 
A‐769662 (10μM) for 3h in MEM with 25mM glucose (HG) ‐/+ 0.125mM octanoate for the last h. Representative 
Immunoblot and densitometry for n=4 mouse hepatocyte preparations, * P < 0.05 relative to respective control; $ P 
< 0.05 octanoate effect. 
 
 at N
ew
castle U
niversity on January 9, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
15 
 
 
FIGURE 2. Effects of metformin on glucose production from oxidized and reduced substrates. After 
overnight culture, mouse hepatocytes were pre‐incubated for 2h in glucose‐free DMEM without or with 100μM 
metformin. The medium was then replaced by fresh glucose-free DMEM containing either 5mM DHA, 2mM xylitol 
(Xyl) or glycerol at 0.25mM or 2mM. After 2h the medium was collected for determination of glucose (A), pyruvate 
and lactate (B) and cell ATP (C). Means ± SD for triplicate plates from 1 hepatocyte isolation. * P < 0.05 relative to DHA; 
$, metformin effect. 
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FIGURE 3. Dihydroxyacetone and xylitol metabolism to glucose, pyruvate and lactate: effects of 
metformin and NADH shuttle inhibitors. Mouse hepatocytes were pre-incubated for 2h in glucose-free DMEM. 
The medium was then replaced by fresh medium containing either 5mM DHA (A-F) or 2mM xylitol (G-L) either 
without (open bars) or with (shaded bars) 0.125mM octanoate and other additions as shown and incubation was for 
2h. Metformin (100μM) and GPi (20μM) were present during both pre‐incubation and final incubation and 
aminooxyacetate (AOA, 200μM) only in the final incubation. A,G. Glucose production; B,H. Pyruvate + lactate 
production; C,I. total production of glucose + pyruvate + lactate, expressed as C3 units; D,J. Glucose % total 
metabolism; E,K. lactate / pyruvate ratio; F,L. Cell G3P. Means ± SD for n= 6-9 (A-F) or 5-7 (G-L) hepatocyte 
preparations, * P < 0.05 relative to respective control; $ P < 0.05 octanoate effect. 
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FIGURE 4. Endogenous mGPDH activity and effects of GPi and metformin. A.B. Activity of endogenous 
mGPDH assayed in permeabilised hepatocytes with the concentrations of GPi (A) or metformin (B) indicated. C-E. 
Hepatocytes were either untreated (Con) or treated with 8 x 108 PFU/ml Adv-SH-mGpd2 (SH) for Gpd2 knock-down 
or with Adv-mGpd2 at 1.6 (L) or 4.8 (H) x 107 PFU/ml for mGPDH overexpression. C. Gpd2/Gapdh mRNA expressed 
relative to untreated control. D. Immunoactivity of mGPDH/GAPDH. E mGPDH enzyme activity. Means ± SD for n= 6-
12 (A,B) or 5-6 (C-E) experiments, * P < 0.05 relative to control. 
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FIGURE 5. The mGPDH inhibitor raises cell G3P but does not mimic metformin. Mouse hepatocytes were 
either untreated or treated with Adv-mGpd2 at 4.8 x 107 PFU/ml (mGPDH-H) for overexpression of mGPDH as in Fig. 
4. After overnight culture they were incubated for 2h in glucose-free DMEM with 50μM or 100μM metformin or with 
80μM GPi (STK017597) as indicated. They were then incubated in fresh medium containing 5mM DHA and the same 
metformin and GPi concentrations for determination of glucose, pyruvate and lactate production. A. Cell G3P; B. 
Glucose production; C. Pyruvate + lactate production; D. Total production of glucose, pyruvate and lactate (C3 units); 
E. Glucose % total metabolism; F. Cell ATP. Means ± SD for 3 hepatocyte preparations. * P < 0.05 relative to 
respective control; $ < 0.05 effect of mGPDH overexpression. 
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FIGURE 6. Overexpression of mGPDH in hepatocytes promotes lower G3P, a reduced mitochondrial 
NADH / NAD redox state and increased glycolysis. Mouse hepatocytes were either untreated (Con) or treated 
with low (L) and high (H) titres of Adv-Gpd2 for overexpression of mGPDH as in Fig. 4. After 20 h culture to allow 
protein overexpression they were incubated for 1 h in MEM containing 25mM glucose and 0.125mM octanoate. A. 
G3P; B, C. 3-hydroxybutyrate / acetoacetate ratio and total 3-hydroxybutyrate + acetoacetate production; D,E. 
Pyruvate and lactate production and lactate / pyruvate ratio; F. Cell ATP. Means ± SD for n= 7-11, * P < 0.05 relative 
to untreated control. 
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FIGURE 7. Overexpression of mGPDH favours metabolism of dihydroxyacetone to pyruvate and lactate 
rather than glucose. Mouse hepatocytes were either untreated or treated for overexpression of mGPDH (L and H) 
as in Fig. 4 and 5. After 20h culture they were incubated for 2h in glucose-free DMEM containing either 5mM DHA (A-
F) or 5mM DHA and 0.125mM octanoate (G-L) without (open bar) or with( shaded bar) 200μM AOA. A,G. Cell G3P; 
B,H. Glucose production; C,I. Pyruvate + lactate; D,J, total production of glucose + pyruvate + lactate expressed as C3 
units; E,K. Glucose % total metabolism; F,L. lactate / pyruvate ratio. Means ± SD for n= 11-12 (A-F) or n= 3-5 (G-L), * P 
< 0.05 effect of mGPDH overexpression, $ P < 0.05 effect of AOA. 
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FIGURE 8. Overexpression of mGPDH favours increased glycerol but not xylitol metabolism. Mouse 
hepatocytes were either untreated or treated for overexpression of mGPDH (L and H) as in Fig. 4 and cultured for 20h 
followed by 2h incubation in glucose-free DMEM.   A-C.  Medium contained 2mM xylitol without (open bar) or with 
(shaded bar) 200μM aminooxyacetate (AOA).  A, Cell G3P; B. total production of glucose + pyruvate + lactate expressed 
as C3 units; C. lactate / pyruvate ratio.    D-I. Medium contained glycerol at either 0.25, 0.5 or 2mM. D, Cell G3P; E. 
Glucose production; F. Pyruvate + lactate; G, total production of glucose + pyruvate + lactate (C3 units); H. Glucose % 
total metabolism; I. lactate / pyruvate ratio. Means ± SD for n= 4-5, * P < 0.05 effect of mGPDH overexpression (A-I); 
$ P < 0.05 effect of AOA (A-C) 
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FIGURE 9. Comparison of metformin and an AMPK activator on DHA metabolism in cells depleted of 
fructose 2,6‐P2. Mouse hepatocytes were either untreated (open bars) or treated (filled bars) with an adenoviral 
vector for expression of kinase-deficient PFK2 (PFK-KD) to deplete cell fructose 2,6-P2 (38).  After 20 h culture they 
were pre-incubated for 2h in glucose-free medium with 100μM metformin or 10μM A‐769662. They were then 
incubated for 2h in fresh medium containing 5mM DHA. A. Glucose production; B. Pyruvate + lactate production; C. 
total production of glucose + pyruvate + lactate (C3 units); D. Glucose % total metabolism; E. lactate / pyruvate ratio; 
F. Cell ATP. Means ± SD for n= 4-6, * P < 0.05; relative to respective control; $, effect of PFK-KD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 at N
ew
castle U
niversity on January 9, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
23 
 
 
 
FIGURE 10. Metformin inhibition of gluconeogenesis from DHA is abolished by inhibitors of PFK1 or 
FBP1. Mouse hepatocytes were incubated for 2h in glucose-free DMEM without (open) or with (shaded) 100μM 
metformin and then for 2h in fresh medium containing 5mM DHA + 200nM S4048 and other additions as indicated: 
aurintricarboxylic acid (ATA) at 25 or 50μM and FBPi at 5μM. A. Glucose production; B Cell glucose 6-P; C. Pyruvate + 
lactate production; D; total production of glucose + pyruvate + lactate, as C3 units; E. Glucose % total metabolism; F. 
Cell ATP. Means ± SD for n= 5-6, * P < 0.05 relative to respective control; $ P < 0.05 metformin effect. 
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FIGURE 11.    Substrate and inhibitor effects on the NADH/NAD redox state.  Octanoate is metabolised in 
mitochondria by β-oxidation generating NADH and FADH, which are oxidised in the electron transport chain, and the 
final end-products: acetoacetate (Acac) and 3-hydroxybutyrate (HOB).  The ratio of HOB/Acac reflects the 
mitochondrial NADH/NAD redox state. It is increased by high metformin and rotenone (Complex I inhibitor) and 
decreased by low metformin and uncoupler, DNP (Fig. 1). It is increased by overexpression of mGPDH which 
catalyses oxidation of G3P with transfer of electrons to the respiratory chain (Fig. 6).   DHA is metabolised to either 
glucose or pyruvate. The latter results in production of NADH (at GAPDH) which is coupled to either formation of 
lactate by lactate dehydrogenase or malate, which is oxidised in mitochondria by the malate-aspartate-shuttle (MAS) 
(Fig. 3,7).   Xylitol metabolism generates NADH during oxidation to xylulose and at GAPDH during formation of 
pyruvate (Fig. 3,8).  Glycerol metabolism generates G3P which is converted to DHAP by either mGPDH, with transfer 
of electrons to the respiratory chain or by cGPDH generating NADH in the cytoplasm which re-oxidized via the MA-
shuttle (Fig. 8).  AOA inhibits the MA-shuttle at the transaminase reaction and increases the lactate / pyruvate ratio 
and G3P and inhibits total xylitol metabolism (Fig. 3,7,8). The MA-shuttle is also inhibited at the aspartate transport 
step by mitochondrial depolarisation (↓ψ).  GPi (80 µM, mGPDH inhibitor) increases G3P (Fig. 5).   mGPDH 
overexpression lowers G3P, increases total glycerol metabolism and favours DHA metabolism to pyruvate and 
lactate relative to glucose (Fig. 6-8).  Octanoate, ATA (PFK1 inhibitor) and fructose 2,6-P2 depletion promote DHA 
metabolism to glucose relative to pyruvate and lactate (Fig. 9,10).  Metformin (100 µM or < 2nmol/mg cell protein) 
promotes decreased DHA metabolism to glucose relative to pyruvate plus lactate and moderately increases the 
lactate / pyruvate ratio and decreases cell G3P (Figs 3,5,9,10). It lowers G6P in conditions of restrained G6P entry 
into the endoplasmic reticulum with a transport inhibitor, S4048 (Fig. 10). 
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